Hematologic effects of inactivating the Ras processing enzyme Rce1

19Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Posttransiational processing of Ras proteins has attracted considerable interest as a potential target for anticancer drug discovery. Rcel encodes an endoprotease that facilitates membrane targeting of Ras and other prenylated proteins by releasing the carboxyl-terminal 3 amino acids (ie, the -AAX of the CAAX motif). Homozygous Rcel mutant embryos (Rce1-/-) die late in gestation. To characterize the role of Rce1 in hematopoiesis, we performed adoptive transfers and investigated cells from the recipients. Rce1-/- fetal liver cells rescued lethally irradiated recipients and manifested normal long-term repopulating potential in competitive repopulation assays. The recipients of Rce1-/- cells developed modest elevations in mature myeloid cells (neutrophils + monocytes), but remained well. Bone marrow cells from mice that received transplants of Rce1-/- activated extracellular signal-related kinase (ERK) normally in response to granulocytemacrophage colony-stimulating factor. These data suggest that pharmacologic inhibitors of Rce1 will have minimal effects on normal hematopoietic cells. © 2003 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Aiyagari, A. L., Taylor, B. R., Aurora, V., Young, S. G., & Shannon, K. M. (2003). Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood, 101(6), 2250–2252. https://doi.org/10.1182/blood-2002-07-2250

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free